Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1992 3
1993 2
1995 2
1996 2
1997 4
1998 4
1999 11
2000 7
2001 7
2002 14
2003 12
2004 15
2005 10
2006 12
2007 14
2008 24
2009 18
2010 22
2011 18
2012 16
2013 26
2014 33
2015 34
2016 30
2017 29
2018 39
2019 42
2020 38
2021 34
2022 31
2023 17
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

488 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological management of cancer pain: Novel therapeutics.
Virgen CG, Kelkar N, Tran A, Rosa CM, Cruz-Topete D, Amatya S, Cornett EM, Urits I, Viswanath O, Kaye AD. Virgen CG, et al. Biomed Pharmacother. 2022 Dec;156:113871. doi: 10.1016/j.biopha.2022.113871. Epub 2022 Oct 19. Biomed Pharmacother. 2022. PMID: 36272265 Free article. Review.
This manuscript discusses cancer pain, risk factors, epidemiology, guidelines for the treatment of cancer pain, personalization of cancer pain therapy, breakthrough pain, cancer-induced peripheral neuropathy, established cancer pain treatment options, and novel emer …
This manuscript discusses cancer pain, risk factors, epidemiology, guidelines for the treatment of cancer pain, personalization of cancer pa …
Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
De Giorgio R, Zucco FM, Chiarioni G, Mercadante S, Corazziari ES, Caraceni A, Odetti P, Giusti R, Marinangeli F, Pinto C. De Giorgio R, et al. Adv Ther. 2021 Jul;38(7):3589-3621. doi: 10.1007/s12325-021-01766-y. Epub 2021 Jun 4. Adv Ther. 2021. PMID: 34086265 Free PMC article. Review.
Fixed-dose combinations of opioids with mu (mu) opioid receptor antagonists, such as oxycodone/naloxone, have become available, but have limited utility in clinical practice because the individual components cannot be independently titrated, creating a risk of breakthrough …
Fixed-dose combinations of opioids with mu (mu) opioid receptor antagonists, such as oxycodone/naloxone, have become available, but have lim …
Breakthrough cancer pain.
Davies AN. Davies AN. Curr Pain Headache Rep. 2014 Jun;18(6):420. doi: 10.1007/s11916-014-0420-9. Curr Pain Headache Rep. 2014. PMID: 24760489 Review.
Breakthrough pain is a distinct pain state that is common in patients with cancer pain and which is associated with significant morbidity in this group of patients. The aim of this article is to highlight important journal articles relating to breakthrough …
Breakthrough pain is a distinct pain state that is common in patients with cancer pain and which is associated with significan …
High-volume patient-controlled epidural vs. programmed intermittent epidural bolus for labour analgesia: a randomised controlled study.
Roofthooft E, Filetici N, Van Houwe M, Van Houwe P, Barbé A, Fieuws S, Rex S, Wong CA, Van de Velde M. Roofthooft E, et al. Anaesthesia. 2023 Sep;78(9):1129-1138. doi: 10.1111/anae.16060. Epub 2023 Jun 20. Anaesthesia. 2023. PMID: 37340620 Clinical Trial.
In a recent study, we compared this with patient-controlled epidural analgesia without a background infusion and found that a programmed intermittent epidural bolus was associated with less breakthrough pain, lower pain scores, higher local anaesthetic consumption a …
In a recent study, we compared this with patient-controlled epidural analgesia without a background infusion and found that a programmed int …
Management of cancer pain due to bone metastasis.
Takei D, Tagami K. Takei D, et al. J Bone Miner Metab. 2023 May;41(3):327-336. doi: 10.1007/s00774-022-01382-y. Epub 2022 Nov 23. J Bone Miner Metab. 2023. PMID: 36418587 Review.
For pain management, it is important to diagnose whether the pain is based on background pain or breakthrough pain due to bone metastasis. In addition, the management goal of cancer pain due to bone metastasis is not only to achieve pain relief but also to prevent p …
For pain management, it is important to diagnose whether the pain is based on background pain or breakthrough pain due to bone …
Opioid Use and Misuse in Pregnancy.
Shatil B, Landau R. Shatil B, et al. Clin Perinatol. 2020 Dec;47(4):769-777. doi: 10.1016/j.clp.2020.08.004. Clin Perinatol. 2020. PMID: 33153661 Review.
Opioids in cancer-related pain: current situation and outlook.
George B, Minello C, Allano G, Maindet C, Burnod A, Lemaire A. George B, et al. Support Care Cancer. 2019 Aug;27(8):3105-3118. doi: 10.1007/s00520-019-04828-8. Epub 2019 May 24. Support Care Cancer. 2019. PMID: 31127436 Review.
Treating Perioperative and Acute Pain in Patients on Buprenorphine: Narrative Literature Review and Practice Recommendations.
Buresh M, Ratner J, Zgierska A, Gordin V, Alvanzo A. Buresh M, et al. J Gen Intern Med. 2020 Dec;35(12):3635-3643. doi: 10.1007/s11606-020-06115-3. Epub 2020 Aug 21. J Gen Intern Med. 2020. PMID: 32827109 Free PMC article. Review.
In short, evidence suggests that sufficient analgesia can be achieved with maintenance of buprenorphine and use of both opioid and non-opioid analgesic options for breakthrough pain. We recommend that clinicians (1) continue buprenorphine in the perioperative or acu …
In short, evidence suggests that sufficient analgesia can be achieved with maintenance of buprenorphine and use of both opioid and non-opioi …
Breakthrough cancer pain and rational drug use.
Olarte JM. Olarte JM. Support Care Cancer. 2017 Apr;25(Suppl 1):11-17. doi: 10.1007/s00520-017-3636-5. Epub 2017 Feb 18. Support Care Cancer. 2017. PMID: 28213817 Free PMC article.
Breakthrough pain in cancer patients: characteristics, prevalence, and treatment.
Patt RB, Ellison NM. Patt RB, et al. Oncology (Williston Park). 1998 Jul;12(7):1035-46; discussion 1049-52. Oncology (Williston Park). 1998. PMID: 9684277 Free article. Review.
The only prospective study of breakthrough pain conducted to date found a 63% prevalence of breakthrough pain in cancer patients referred to a pain service. ...Breakthrough pain is currently managed with oral or parenteral breakthrough …
The only prospective study of breakthrough pain conducted to date found a 63% prevalence of breakthrough pain in …
488 results